Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life

Publisher: Karger

E-ISSN: 2296-5262|25|1|47-52

ISSN: 2296-5270

Source: Oncology Research and Treatment, Vol.25, Iss.1, 2002-03, pp. : 47-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract